Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharma a/s - dexlansoprazole - capsules modified release - 60 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

takeda pharma a/s - dexlansoprazole - capsules modified release - 30 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m+) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, zoladex shrinks the lesions and reduces the symptoms, including pain. zoladex also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;   - injection (depot) - 3.6 mg - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin - zoladex 3.6 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - goserelin as acetate - implant - goserelin as acetate 3.6 mg/unit - goserelin - goserelin - treatment of prostate cancer suitable for hormonal manipulation. breast cancer in pre-menopausal women suitable for hormone manipulation.endometriosis. assisted reproduction: pituitary down regulation in preparion for superovulation. endometrial thinning: zoladex is indicated for the prethinning of the utetine endometrium prior ro endometrial ablation or resection. uterine fibroids: for reduction of fibroid size prior to surgery.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agnova technologies pty ltd - cyanazine - water dispersible granule - cyanazine triazine active 900.0 g/kg - herbicide - chickpea | faba bean | field pea | lentil | onion | pea | potato | processing pea | sweet corn | vetch | pulse | sweetcorn - annual or wimmera ryegrass | barley grass | black bindweed | blackberry nightshade | capeweed | chickweed | clover | cotulas | crassula | deadnettle | dock | erodium, crowfoot or storksbill | fat hen | fumitory | great, ripgut or kingston brome | hedge or wild mustard | mountain sorrel/purple calandrinia | mouse-ear chickweed | nettle | plantain | prickly lettuce | redshank,slim or spleen amaranth | rough poppy | sorrel | sow or milk thistle | spear or black thistle | stagger weed | stinging or dwarf nettle | three cornered jack or doublegee | turnip weed | wild radish or radish weed | wild turnip | wireweed, knotweed or hogweed | acetosella vulgaris | amaranthus cruentus | annual bindweed | annual dwarf nettle | annual nettle | annual storksbill | bilderdykia convolvulus | black nightshade | brassica campestris | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | broadleaf dock | brome grass | buckwheat | climbing buckwheat | common chickweed | common plantain | common sowthistle | crambling mus

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin -

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 10.8 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)] . in controlled studies of patients with advanced prostatic cancer comparing zoladex 3.6 mg to orchiectomy, the long-term endocrine responses and objective responses were similar between the two treatment arms. additionally, duration of survival was similar between the two treatment arms in a major comparative trial. in controlled studies of patients with advanced prostatic cancer, zoladex 10.8 mg implant produced pharmacodynamically similar effect in terms of suppression of serum testosterone to that achieved wit